PA8575501A1 - NEW COMBINATION - Google Patents
NEW COMBINATIONInfo
- Publication number
- PA8575501A1 PA8575501A1 PA20038575501A PA8575501A PA8575501A1 PA 8575501 A1 PA8575501 A1 PA 8575501A1 PA 20038575501 A PA20038575501 A PA 20038575501A PA 8575501 A PA8575501 A PA 8575501A PA 8575501 A1 PA8575501 A1 PA 8575501A1
- Authority
- PA
- Panama
- Prior art keywords
- new combination
- phosphodesterase
- antigonist
- gmpc
- pde5
- Prior art date
Links
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LAS COMBINACIONES QUE COMPRENDEN A) UN INHIBIDOR DE FOSFODIESTERASA DE TIPO 5 (PDE5) ESPECIFICA DE MONOFOSFATO DE GUANOSINA CICLICO (GMPC) Y B) UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II SON UTILES PARA TRATAR LA HIPERTENSION.THE COMBINATIONS THAT INCLUDE A) A TYPE 5 PHOSPHODESTERASE INHIBITOR (PDE5) SPECIFY OF CYCLIC GUANOSINE MONOPHOSPHATE (GMPC) AND B) AN ANTIGONIST OF THE ANGIOTENSIN II RECEIVER ARE USEFUL TO TREAT HYPERTENSION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0214784.1A GB0214784D0 (en) | 2002-06-26 | 2002-06-26 | Novel combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8575501A1 true PA8575501A1 (en) | 2003-12-30 |
Family
ID=9939342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20038575501A PA8575501A1 (en) | 2002-06-26 | 2003-06-13 | NEW COMBINATION |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1524996A2 (en) |
| JP (1) | JP2005531627A (en) |
| KR (1) | KR20050013156A (en) |
| CN (1) | CN1662257A (en) |
| AR (1) | AR040337A1 (en) |
| AU (1) | AU2003242895A1 (en) |
| BR (1) | BR0312030A (en) |
| CA (1) | CA2491002A1 (en) |
| GB (1) | GB0214784D0 (en) |
| GT (1) | GT200300124A (en) |
| MX (1) | MXPA04012569A (en) |
| NO (1) | NO20050400L (en) |
| PA (1) | PA8575501A1 (en) |
| PE (1) | PE20040868A1 (en) |
| PL (1) | PL375079A1 (en) |
| RU (1) | RU2004136276A (en) |
| TW (1) | TW200404546A (en) |
| UY (1) | UY27863A1 (en) |
| WO (1) | WO2004002461A2 (en) |
| ZA (1) | ZA200409532B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| US7756327B2 (en) * | 2002-07-26 | 2010-07-13 | Olympus Corporation | Image processing system having multiple imaging modes |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| BRPI0502411A (en) * | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | process of developing substances as potent and selective inhibitors of phosphodiesterase isoforms of types 1 to 5 (pde1, pde2, pde3, pde4, pde5) based on diocleine, fluranol or analogs and their pharmaceutical compositions for the study and treatment of cardiovascular disease and associated products |
| WO2006132460A1 (en) | 2005-06-10 | 2006-12-14 | Dong-A Pharmaceutical.Co., Ltd. | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative |
| EP1909793A2 (en) * | 2005-07-15 | 2008-04-16 | Proxomed Medizintechnik GmbH | Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors |
| WO2007047978A2 (en) * | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| EP2021000A2 (en) * | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| RU2345763C1 (en) * | 2007-04-26 | 2009-02-10 | ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" | Method for reduction and prevention of cardiovascular by-effects induced by application of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction in men |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DK1049695T3 (en) * | 1997-11-12 | 2002-05-13 | Bayer Ag | 2-Phenyl-substituted imidazotriazinones as phosphodiesterase inhibitors |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| SK4562002A3 (en) * | 1999-10-11 | 2003-04-01 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
| CN1446084A (en) * | 2000-08-11 | 2003-10-01 | 辉瑞大药厂 | Treatment of insulin resistance syndrome |
-
2002
- 2002-06-26 GB GBGB0214784.1A patent/GB0214784D0/en not_active Ceased
-
2003
- 2003-06-04 GT GT200300124A patent/GT200300124A/en unknown
- 2003-06-13 PA PA20038575501A patent/PA8575501A1/en unknown
- 2003-06-16 CN CN03814574XA patent/CN1662257A/en active Pending
- 2003-06-16 WO PCT/IB2003/002657 patent/WO2004002461A2/en not_active Ceased
- 2003-06-16 MX MXPA04012569A patent/MXPA04012569A/en unknown
- 2003-06-16 CA CA002491002A patent/CA2491002A1/en not_active Abandoned
- 2003-06-16 BR BR0312030-9A patent/BR0312030A/en not_active IP Right Cessation
- 2003-06-16 JP JP2004517093A patent/JP2005531627A/en not_active Withdrawn
- 2003-06-16 AU AU2003242895A patent/AU2003242895A1/en not_active Abandoned
- 2003-06-16 KR KR10-2004-7021041A patent/KR20050013156A/en not_active Ceased
- 2003-06-16 EP EP03761725A patent/EP1524996A2/en not_active Withdrawn
- 2003-06-16 RU RU2004136276/15A patent/RU2004136276A/en not_active Application Discontinuation
- 2003-06-16 PL PL03375079A patent/PL375079A1/en not_active Application Discontinuation
- 2003-06-20 TW TW092116851A patent/TW200404546A/en unknown
- 2003-06-24 PE PE2003000636A patent/PE20040868A1/en not_active Application Discontinuation
- 2003-06-24 UY UY27863A patent/UY27863A1/en not_active Application Discontinuation
- 2003-06-24 AR ARP030102252A patent/AR040337A1/en not_active Application Discontinuation
-
2004
- 2004-11-25 ZA ZA200409532A patent/ZA200409532B/en unknown
-
2005
- 2005-01-25 NO NO20050400A patent/NO20050400L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040868A1 (en) | 2004-11-25 |
| BR0312030A (en) | 2005-03-22 |
| TW200404546A (en) | 2004-04-01 |
| PL375079A1 (en) | 2005-11-14 |
| RU2004136276A (en) | 2005-09-10 |
| UY27863A1 (en) | 2003-12-31 |
| GB0214784D0 (en) | 2002-08-07 |
| WO2004002461A2 (en) | 2004-01-08 |
| CA2491002A1 (en) | 2004-01-08 |
| GT200300124A (en) | 2004-03-17 |
| CN1662257A (en) | 2005-08-31 |
| JP2005531627A (en) | 2005-10-20 |
| AU2003242895A1 (en) | 2004-01-19 |
| KR20050013156A (en) | 2005-02-02 |
| EP1524996A2 (en) | 2005-04-27 |
| NO20050400L (en) | 2005-03-29 |
| MXPA04012569A (en) | 2005-04-19 |
| WO2004002461A3 (en) | 2004-05-13 |
| AR040337A1 (en) | 2005-03-30 |
| ZA200409532B (en) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8575501A1 (en) | NEW COMBINATION | |
| DE60310131T8 (en) | DEVICE FOR GENERATING EXHAUST GAS | |
| IS6689A (en) | Phosphonate-nucleotide analogues and methods used to select and create them | |
| DK1583541T3 (en) | Compounds and Methods to Increase Neurogenesis | |
| HN2003000285A (en) | NEW ESPIROCONDENSED QUINAZOLINONES AND ITS USE AS PHOSPHODIESTERASE INHIBITORS | |
| IL162728A0 (en) | Methods of inducing differentiationin stem cells, methods of generating tissue using scaffold matrices derived from micro-organs and stem c | |
| ATE484231T1 (en) | DEVICE FOR PREDICTING MUSCLE/SKELETAL DISEASES | |
| MA29154B1 (en) | GEMCITABINE AMIDE PROMEDICAMENT, COMPOSITIONS AND USES THEREOF | |
| PA8574201A1 (en) | NEW COMBINATION | |
| EP1534268A4 (en) | INHIBITORS OF TYROSINE KINASE | |
| AR029838A1 (en) | SUBSTITUTED BENZONITROGEN HETEROCICLES | |
| MY209504A (en) | Led lighting device having additional function | |
| ECSP045466A (en) | PEPTIDE-DISFORMILASE INHIBITORS | |
| UY27192A1 (en) | PEPTIDE DEFORMILASE INHIBITORS | |
| DE60324418D1 (en) | Non-nucleoside inhibitors of the reverse transcriptase | |
| DE69835288D1 (en) | COMBINATION THERAPY FOR MODULATING THE HUMAN SEXUAL REACTION | |
| DE602004009824D1 (en) | ANALYSIS OF MASS SPECTRAL DATA IN THE QUIET AREAS | |
| EP1496897A4 (en) | INHIBITORS OF TYROSINE KINASES | |
| NO20032762L (en) | Activity Management Device | |
| HN2003000071A (en) | COMBINATIONS OF A BINDING ALFA-2-DELTA WITH A SELECTIVE INHIBITOR OF THE CYCLOOXYGENASA-2 | |
| UY31421A1 (en) | ARYLINDENOPIRIMIDINS AND ITS USE AS ADENOSINE A2A | |
| DOP2003000649A (en) | NEW COMBINATION | |
| DOP2003000645A (en) | NEW COMBINATION | |
| NO20044186L (en) | Peptide deformylaseinhibitorer | |
| UY26893A1 (en) | PHARMACEUTICAL COMBINATION OF ANTAGONISTS OF ANGIOTENSIN II AND INHIBITORS OF THE CONVERSION ENZYME OF ANGIOTENSIN I |